Advances in the Gut‐Lung Axis and Bronchial Asthma: From Mechanisms to Therapeutic Potential
Clinical and Translational Allergy · 2025-12 · 15 (12)
DOI: 10.1002/clt2.70128 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Allergy, online erschienen am 27.11.2025. Verfasst von Ting Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine, Zunyi Medical University, Zunyi, Guizhou, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guizhou Provincial Basic Research Program.
Abstract (Originalsprache)
Background
Bronchial asthma (hereafter referred to as asthma) is a heterogeneous disease characterized by chronic airway inflammation, airway hyperresponsiveness (AHR), and reversible airflow limitation. Recent advancements in the “gut‐lung” axis concept have elucidated the intricate immunometabolic crosstalk between the gastrointestinal tract and pulmonary system, offering novel insights into the pathogenesis and therapeutic strategies for asthma.
Objective
Exploring the research progress of the “gut‐lung” axis in bronchial asthma, providing new insights into the pathogenesis and treatment of asthma.
Methods
This article reviewed a large number of relevant studies, elucidating the role of the “gut‐lung” axis in bronchial asthma, and further discussing the potential of the microbiota in the treatment of bronchial asthma.
Conclusion
Gut microbiota and their metabolites exert profound effects on pulmonary immune homeostasis through immune modulation, metabolic signaling, and neuroendocrine pathways, which are critically implicated in asthma pathogenesis. Conversely, systemic immune dysregulation in asthma may reciprocally induce intestinal barrier dysfunction. Asthma is a variable disease here. It may be that some of this variability relates to different diets or environmental/gut exposures although this needs to be confirmed in human studies. This review comprehensively delineates the mechanistic role of the gut‐lung axis in asthma, encompassing microbiota‐immune system interactions, regulatory effects of microbial‐derived metabolites such as short‐chain fatty acids (SCFAs) and bile acids, and microbiota‐targeted therapeutic approaches including probiotics, dietary interventions, and metabolite‐based therapies. Furthermore, we also discuss the limitations and future development directions of current research to provide new ideas for precision treatment of asthma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Medicine, Zunyi Medical University, Zunyi, Guizhou, China.
- Respiratory Medicine, Guizhou Provincial People's Hospital, Guiyang City, Guizhou Province, China.
ORCID-Profile: Hongmei Yao
Förderung
- Guizhou Provincial Basic Research Program
Zitieren
APA
Zheng, T., Huang, Y., & Yao, H. (2025). Advances in the Gut‐Lung Axis and Bronchial Asthma: From Mechanisms to Therapeutic Potential. Clinical and Translational Allergy, 15(12). https://doi.org/10.1002/clt2.70128
Vancouver
Zheng T, Huang Y, Yao H. Advances in the Gut‐Lung Axis and Bronchial Asthma: From Mechanisms to Therapeutic Potential. Clinical and Translational Allergy. 2025;15(12). doi:10.1002/clt2.70128
BibTeX
@article{Zheng2025,
author = {Zheng, Ting and Huang, Yi and Yao, Hongmei},
title = {Advances in the Gut‐Lung Axis and Bronchial Asthma: From Mechanisms to Therapeutic Potential},
journal = {Clinical and Translational Allergy},
year = {2025},
volume = {15},
number = {12},
doi = {10.1002/clt2.70128}
}
EUVIMED